|
|
1. MARKET OVERVIEW
|
Influencer Market Insights |
World Market Trajectories |
Patient Derived Xenograft/PDX Models – Global Key Competitors Percentage Market Share in 2022 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS
|
3. MARKET TRENDS & DRIVERS
|
4. GLOBAL MARKET PERSPECTIVE
|
World Recent Past, Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Patient Derived Xenograft / PDX Models Market Analysis of Annual Sales in US$ for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Mice Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Mice Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Rat Model by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Rat Model by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Biomarker Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Biomarker Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
World 8-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030 |
|
UNITED STATES
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
USA 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
CANADA
|
Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Canada 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
JAPAN
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Japan 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
CHINA
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
China Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
China 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
EUROPE
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
FRANCE
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
France Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
France 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
GERMANY
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Germany 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
ITALY
|
Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Italy 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
UNITED KINGDOM
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
UK 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
REST OF EUROPE
|
Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Rest of Europe 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
ASIA-PACIFIC
|
Patient Derived Xenograft / PDX Models Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Asia-Pacific 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
REST OF WORLD
|
Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Application - Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development, Basic Cancer Research and Biomarker Analysis for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by End-Use - Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations and Academic & Research Institutes for the Years 2023 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Patient Derived Xenograft / PDX Models by Model - Mice Model and Rat Model - Independent Analysis of Annual Sales in US$ for the Years 2022 through 2030 and % CAGR |
Rest of World 8-Year Perspective for Patient Derived Xenograft / PDX Models by Model - Percentage Breakdown of Value Sales for Mice Model and Rat Model for the Years 2023 & 2030 |
|
|